Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2023-08-29

Clinical Trial Update: Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for adrabetadex in Niemann-Pick disease type C1 (NPC1) has terminated after Phase 2/3; results posted were in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Adrabetadex (adrabetadex)

Snippet

Sponsor: Mandos LLC | Conditions: Niemann-Pick Disease, Type C | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2023-08-29